Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference
View HTML
Toggle Summary Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
BURLINGTON, Mass. , Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference . The virtual
View HTML
Toggle Summary Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee
AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of
View HTML
Toggle Summary Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
Initial findings from proof-of-concept trial in patients undergoing bunionectomy support expansion of the study to include 36 additional patients Data from the trial, including the expansion cohort, anticipated by year-end BURLINGTON, Mass. , Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics,
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)
Data published in Drugs in R&D confirms extended-release PK profile of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with shoulder OA Plasma PK data indicate the total and maximal exposure to triamcinolone acetonide (TA) was approximately two-thirds lower in
View HTML
Toggle Summary Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
ZILRETTA® ( triamcinolone acetonide extended-release injectable suspension) net sales were $28 .2 million in Q2 2021, reflecting growth of 15% over the previous quarter Net loss in Q2 2021 decreased by $10 .4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on
View HTML
Toggle Summary Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
BURLINGTON, Mass. , July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET .
View HTML
Toggle Summary Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
BURLINGTON, Mass. , July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar , Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion’s audit committee.
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , July 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
View HTML
Toggle Summary Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
BURLINGTON, Mass. , June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference .
View HTML